A Phase 1/2 Study Evaluating the Safety, Tolerability and Preliminary Antitumor Activity of COM701 in Combination With BMS-986207 (Anti-TIGIT Antibody) and Nivolumab in Subjects With Advanced Solid Tumors
COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors
Sponsor: Compugen Ltd.
Enrolling: Male and Female Patients
IRB Number: AAAT4904
U.S. Govt. ID: NCT04570839
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this clinical trial is to find a safe and tolerated dose of the study treatment COM701 in combination with BMS-986207 and nivolumab for the treatment of advanced solid tumors. These drugs are being developed to fight cancer by using your immune system to fight the cancer cells (known as immunotherapies). These study drugs are also known as immune checkpoint inhibitors. The study drug COM701 works by blocking a protein (PVRIG) that is found on T-cells. That protein inhibits the T-cells from working effectively against cancer cells. By blocking PVRIG we hope that the study drug will make the T cells in your body more able to fight the cancer cells. BMS-986201 is a blocker of a protein called TIGIT found on T cells. By blocking TIGIT, the study drug helps your T cells fight the cancer cells. BMS-986201 is a blocker of a protein call TIGIT found on T cells. By blocking TIGIT it helps your T cells fight the cancer cells. Nivolumab is a PD1 blocker, a protein that activates the immune system to recognize and kill cancer cells. Cancers include: Bladder cancer, brain and spinal tumors, breast cancer, colon cancer, rectal cancer, esophageal cancer, cervical cancer, ovarian cancer, uterine (endometrial) cancer, head and neck/oral cancers, kidney cancer, adrenal cancer, liver cancer, lung cancer, skin cancer, melanoma, pancreatic cancer, prostate cancer, soft tissue sarcoma, stomach cancer, testicular cancer, and thyroid cancer.
Investigator
Benjamin Izar, MD
Do You Qualify?
Are you at least 18 years of age? Yes No
Have you been diagnosed with locally advanced or metastatic cancer? Yes No
Have you exhausted all available standard therapies for your type of cancer? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162